• Explore /
  • Poster
  • / Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies.

Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies.

Abstract Video & Slides Poster

Authors

null

Hideaki Bando

Aichi Cancer Center Hospital, Aichi, Japan

Hideaki Bando , Ichiro Kinoshita , Shanu Modi , Junji Tsurutani , Yung-Jue Bang , Hiroji Iwata , Yuta Sato , Shunsuke Nakatani , Caleb C. Lee , Masahiro Sugihara , Yasuyuki Okuda , Shunji Takahashi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Other Head and Neck Cancer (Salivary, Thyroid)

Clinical Trial Registration Number

NCT02564900 and NCT03383692

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 6079)

DOI

10.1200/JCO.2021.39.15_suppl.6079

Abstract #

6079

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Sara A. Hurvitz

First Author: Xichun Hu

First Author: Yelena Y. Janjigian

First Author: Bob T. Li